Revenues growing for Astrazeneca, which closed the first half of 2021 with a revenue of $15,54 billion, up 23% over the same period in 2020. In the second quarter alone, revenues rose 31% to $8,22 billion. Excluding the contribution of the Covid-19 vaccine, revenue increased 14% in the half year and 17% in the quarter, the company noted.
And speaking of the vaccine, the company has provided more than that to date 1 billion doses to 170 countries at an average price per dose of $3,7. Whey sales Astrazeneca in the second quarter tripled compared to the previous 3 months, rising to 894 million, while from January to June sales amounted to 1,17 billion dollars. Important numbers that arrive despite the obstacles encountered in Europe following the rare side effects that have led several states (including Italy) to impose limitations on the administration of serum to younger citizens. We must also take into account the fact that the vaccine is not yet used in the USA, where according to the latest indications the Anglo-Swedish company should present the appropriate request for authorization to market in the second half of this year, significantly behind the previously announced deadlines .
As anticipated on March 30, AstraZeneca reiterated that during the pandemic it will not profit from the sale of the vaccine and that whey development and manufacturing costs reduced second-quarter earnings per share by a cent, which fell 28 percent to 42 cents versus 58 cents in the comparable quarter of 2020. Overall, for the quarter, the loss is 13 million.
. It should also be noted that while AstraZeneca did not provide forecasts for revenues from vaccine sales this year, rivals Pfizer, Moderna and Johnson & Johnson brought in $33,5 billion, $19,2 billion and $2,5 billion, respectively. XNUMX billion are the estimates on revenues deriving from the sales of anti-Covid vaccines.
“Astrazeneca – he said the managing director Pascal Soriot – had another period of strong growth thanks to solid performance across all regions and regions. As a result, we delivered further earnings growth, supported ongoing launches and continued our investment in R&D." In particular, Alexion “will allow us to improve our pipeline, extending the company's presence in rare diseases and immunology. Following the successful acquisition of Alexion, today we update our guidance for the full year 2021; our long-term goals to accelerate scientific discovery, invest for sustainable growth and deliver greater patient benefits remain unchanged.”
on the London Stock Exchange, the title Astrazeneca gains 0,27% to £8.288.
